Table 2.

Original data extracted from included clinical trials.

Study	Year	Patients	Intervention	DCR(%)	ORR(%)	mPFS(months)	mOS(months)	Grade 3-4 AE(%)
Herbst et al. (18)	2019	27	Pembrolizumab Ramucirumab	85.0%	30.0%	9.7(4.6-27.6)	26.2(11.8-NR)	NR
Galffy et al. (19)	2020	41	Avelumab Axitinib	70.7%	31.7%	5.5(2.5-7.0)	NR	58.5%
Bang et al. (20)	2020	28	Durvalumab Ramucirumab	57.0%	11.0%	2.7(1.6-5.8)	11.0(6.2-15.2)	32.1%
Zhou et al. (21)	2021	45	Camrelizumab Anlotinib	82.2%	13.3%	8.2(4.3-12.1)	12.7(10.2-15.1)	03.7%
Puri et al. (22)	2021	18	Nvolumab Ipilimumab Nintedanib	61.0%	22.0%	2.7(1.4-NR)	7.7(5.0-NR)	NR
Pan et al. (23)	2021	10	Camrelizumab Chemotherapy Apatinib	80.0%	20.0%	NR	NR	NR
Zhou et al. (24)	2021	105	Camrelizumab Apatinib	73.3%	27.6%	5.7(4.5-8.8)	15.5(10.9-24.5)	69.5%
Han et al. (25)	2021	68	TQB-2450(PD-L1) Anlotinib	73.5%	30.9%	6.9(5.3-12.4)	NR	67.7%
Leal et al. (26)	2021	68	Nivolumab Sitravatinib	NR	16.0%	6.0	15(9.3-21.1)	60.0%
Fang et al. (27)	2022	19	Atezolizumab Bevacizumab	68.4%	15.8%	2.8	NR	40.0%
Reckmap et al. (28)	2022	69	Pembrolizumab Ramucirumab	75.0%	22.0%	4.5(4.2-6.1)	14.5(13.9-16.1)	42.0%
Lv et al. (29)	2022	34	Nivolumab Recombinant human endostatin	64.7%	41.2%	6.8(1.1-12.1)	17.1(6.6-27.6)	11.8%
Lu et al. (30)	2022	158	Sintilimab Bevacizumab biosimilar IBI305 Chemotherapy	86.1%	48.1%	7.2(6.6-9.3)	NR	59.5%
Lee et al. (31)	2022	24	Atezolizumab Bevacizumab	87.5%	12.5%	5.6(4.1-7.1)	14.0(10.7-17.4)	4.2%
Herzog et al. (32)	2022	21	Atezolizumab Ramucirumab	81.0%	4.80%	3.4	16.5	43.0%
Gao et al. (33)	2022	25	Camrelizumab Apatinib	84.0%	32.0%	6.0(3.5-8.1)	13.3(6.4-18.8)	84.0%
Neal et al. (34)	2022	81	Atezolizumab Cabozantinib	80%	19.0%	4.5(3.5-5.6)	13.8(7.2-15.7)	52.0%
Gao et al. (35)	2021	47	Tislelizumab Sitravatinib	86.0%	14.0%	5.2(4.1-5.9)	NR	68.0%
Gao et al. (36)	2022	43	Camrelizumab Apatinib	58.1%	18.6%	2.8(1.9-5.5)	NR	65.1%